Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -99.00% | 0.00% | 0.00% |
04-12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
03-21 | North American Morning Briefing : Investors -2- | DJ |
Sales 2021 | 17.5M 23.89M | Sales 2022 | 49.72M 67.87M | Capitalization | 111M 152M |
---|---|---|---|---|---|
Net income 2021 | -64M -87.36M | Net income 2022 | -51M -69.62M | EV / Sales 2021 | 5.55 x |
Net Debt 2021 | 7.2M 9.83M | Net Debt 2022 | 12.95M 17.67M | EV / Sales 2022 | 2.49 x |
P/E ratio 2021 |
-1.12
x | P/E ratio 2022 |
-1.95
x | Employees | 125 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 96.32% |
Latest transcript on RVL Pharmaceuticals plc
1 day | -99.00% |
Managers | Title | Age | Since |
---|---|---|---|
Sergio Alegre
CMP | Compliance Officer | - | 16-07-31 |
James Schaub
COO | Chief Operating Officer | 42 | 15-12-31 |
Michael Depetris
AUD | Comptroller/Controller/Auditor | - | 22-04-17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gregory Cowan
BRD | Director/Board Member | 70 | 18-12-31 |
Alisa Lask
BRD | Director/Board Member | 53 | 22-08-09 |
Michael DeBiasi
BRD | Director/Board Member | 48 | 19-09-30 |
1st Jan change | Capi. | |
---|---|---|
0.00% | 111 | |
-4.53% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- RVLPQ Stock